FindTrial
Sign In

diagnosis of invasive fungal infections

To evaluate the role of 1,3-Beta-D-Glucan for diagnosing invasive fungal infections in adults in ICU- a prospective observational study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055119
Enrollment
102
Registered
2023-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B376- Candidal endocarditis

Interventions

None listed

Sponsors

Max Super Speciality Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Candida Score >3 for Invasive Candidiasis OR 2)Fulfilling Meersseman criteria for Invasive Aspergillosis

Exclusion criteria

Exclusion criteria: 1)Patients 2)Patients already on antifungal treatment 3)Unwillingness to participate in study

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of 1,3-beta-D-Glucan assay for the diagnosis of invasive fungal infections in adults admitted in ICUTimepoint: 1 year—

Secondary

MeasureTime frame
To calculate mortality and duration of stay in ICU of IFIs in a tertiary care medical ICU.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Dinesh Chandra Bishnoi

Max Super Speciality Hospital

omender.singh@maxhealthcare.com9205076072

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026